HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Shigefumi Suehiro Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mizuguchi, S. Articles by Suehiro, S. Search for Related Content PubMed PubMed Citation Articles by Mizuguchi, S. Articles by Suehiro, S. Related Collections Lung - cancer Related Article

Ann Thorac Surg 2007;83:216-221
© 2007 The Society of Thoracic Surgeons

---

Original Articles: General Thoracic

Clinical Value of Serum Cytokeratin 19 Fragment and Sialyl-Lewis X in Non-Small Cell Lung Cancer

^a Department of Thoracic Surgery, Osaka City University Hospital, Osaka, Japan
^b Department of Thoracic Surgery, Bell Land General Hospital, Osaka, Japan
^c Department of Cardiovascular Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan

Accepted for publication August 23, 2006.

^_* Address correspondence to Dr Mizuguchi, Department of Thoracic Surgery, Osaka City University Medical School, 1-4-3 Asahimachi, Abeno-ku, Osaka 545-8585, Japan (Email: m1293795{at}msic.med.osaka-cu.ac.jp).

BACKGROUND: This study aimed to establish the clinical significance of preoperative serum cytokeratin 19 fragment (CYFRA21-1) and sialyl-Lewis x (SLex) as prognostic markers.

METHODS: The study involved 272 patients (181 male, 91 female; median age 69 years; range, 32 to 92) with non-small cell lung cancer (NSCLC) who underwent pulmonary resection with mediastinal lymph node dissection. Tumor markers carcinoembryonic antigen (CEA), squamous cell carcinoma antigen (SCC), CYFRA21-1, and SLex were examined.

RESULTS: A log-rank test revealed that age, gender, performance status, CEA, SCC, CYFRA21-1, and SLex were associated with the survival rate. By multivariate analysis, age, gender, performance status, CYFRA21-1 (risk ratio, 2.42) and SLex (risk ratio, 6.18) were independent prognostic factors. For patients positive for both markers, the relative risk was 6.10 compared with patients negative for both markers. The patients were divided into three groups: negative for both CYFRA21-1 and SLex (n = 97); positive for either marker (n = 136); and positive for both markers (n = 39). The 1-, 3-, and 5-year survival rates were the following: 98%, 82%, and 75% in the first group; 90%, 63%, and 49% in the second group; and 62%, 31%, and 25% in the third group (p < 0.001). Sixty-four percent of patients positive for both markers were histologic stage III/IV, and 68% of patients negative for both markers were stage I.

CONCLUSIONS: Serum CYFRA21-1 and SLex were prognostic markers for NSCLC. Their combination should contribute to the classification of NSCLC patients. Preoperative staging should be carefully performed in patients positive for both tumor markers.

Related Article

Invited commentary

Thomas D’Amico
Ann. Thorac. Surg. 2007 83: 221-222. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

				T. Uenishi, O. Yamazaki, H. Tanaka, S. Takemura, T. Yamamoto, S. Tanaka, S. Nishiguchi, and S. Kubo Serum Cytokeratin 19 Fragment (CYFRA21-1) as a Prognostic Factor in Intrahepatic Cholangiocarcinoma Ann. Surg. Oncol., February 1, 2008; 15(2): 583 - 589. [Abstract] [Full Text] [PDF]

				T. D'Amico Invited commentary Ann. Thorac. Surg., January 1, 2007; 83(1): 221 - 222. [Full Text] [PDF]